Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859845 | 0.86 | DRD4 (0.31) | KDM1A | |
| SCHEMBL13605225 | 0.82 | KDM1A (0.38) | KDM1ABDKRB2CHRM2CHRM3 | |
| SCHEMBL16508758 | 0.79 | KDM4E (0.33) | — | |
| SCHEMBL9946179 | 0.79 | — | — | |
| SCHEMBL20154538 | 0.75 | — | — | |
| SCHEMBL14885151 | 0.75 | CHRM2 (0.34) | BDKRB2CHRM2CHRM3 | |
| SCHEMBL14546631 | 0.74 | — | — | |
| SCHEMBL15259314 | 0.74 | — | — | |
| SCHEMBL16110021 | 0.73 | KDM1A (0.36) | KDM1ABDKRB2CHRM2CHRM3 | |
| SCHEMBL16487530 | 0.73 | CHRM2 (0.33) | BDKRB2CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168082-B2 | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| US-20200157091-A1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157091-A1 | PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS | KDM1A, KDM1B, KDM2A | KDM1A 1/4885BDKRB2 2953/4885CHRM2 570/4885 |
| US-11168082-B2 | Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors | KDM1A, KDM1B, KDM2A | KDM1A 1/4885BDKRB2 2953/4885CHRM2 570/4885 |
| US-20210130327-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | KDM1A 1912/4885BDKRB2 1328/4885CHRM2 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.